Parietin Cyclodextrin-Inclusion Complex as an Effective Formulation for Bacterial Photoinactivation

Abdallah Mohamed Ayoub1,2, Bernd Gutberlet1, Eduard Preis1

  • 1Department of Pharmaceutics and Biopharmaceutics, University of Marburg, Robert-Koch-Str. 4, 35037 Marburg, Germany.

Pharmaceutics
|February 26, 2022
PubMed

Insights

This study shows that complexing parietin (PTN) with (2-hydroxypropyl)-β-cyclodextrin (HP-β-CD) significantly improves its solubility and photostability, enhancing its effectiveness in antimicrobial photodynamic therapy (aPDT) against resistant bacteria.

Area of Science:

  • Photodynamic Therapy
  • Antimicrobial Resistance
  • Natural Products Chemistry

Background:

  • Multidrug-resistant bacteria pose a significant public health threat.
  • Antimicrobial photodynamic therapy (aPDT) offers an alternative treatment with lower resistance development.
  • Parietin (PTN), a natural anthraquinone, shows potential for aPDT but suffers from poor solubility and aggregation.

Purpose of the Study:

  • To investigate the complexation of PTN with (2-hydroxypropyl)-β-cyclodextrin (HP-β-CD).
  • To enhance PTN's solubility, photophysical properties, and phototoxicity against bacteria.
  • To evaluate PTN/HP-β-CD complexes as a potential therapeutic strategy.

Main Methods:

  • Phase solubility method to determine solubilization behavior and complexation constant.
  • Physicochemical characterization of PTN/HP-β-CD complexes.
  • Uric acid method to assess photodynamic activity and blue light-mediated photodegradation.

Main Results:

  • Complexation with HP-β-CD increased PTN's aqueous solubility by 28-fold.
  • PTN/HP-β-CD complexes exhibited enhanced photostability compared to free PTN.
  • Irradiated PTN/HP-β-CD complexes reduced bacterial viability of *Staphylococcus saprophyticus* and *Escherichia coli* by >4.8 and >1.0 log, respectively.

Conclusions:

  • Complexation with HP-β-CD effectively overcomes PTN's limitations of poor solubility, aggregation, and photoinstability.
  • PTN/HP-β-CD complexes demonstrate improved efficacy in aPDT against resistant bacteria.
  • This approach offers a promising new avenue for treating infections caused by multidrug-resistant pathogens.

Related Concept Videos